Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review
Iovance Biotherapeutics Inc IOVA
$4.07
▼ -13.22%
($-0.62)
⬇️ Below Yest. Low
🔥 High Short Interest
📅 Earnings This Week
Open
$4.43
Prev Close
$4.69
Day Range
$4.02 – $4.55
52W Range
$1.76 – $5.64
Market Cap
$1.82B
Beta
0.70
EPS (TTM)
$-0.95
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2008-06-20 |
| Shares Out. | 446,500,000 |
| Website | iovance.com/ ↗ |
| Phone | 13026974590 |
| Employees | 975 |
| Revenue | $71.4M |
| Gross Profit | $28.9M |
| Net Income | -$79.0M |
| Free Cash Flow | -$305.0M |
| Total Assets | $925.7M |
| Total Liabilities | $203.9M |
| Equity | $721.8M |
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics Inc is a publicly traded company under the ticker symbol IOVA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)